Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues

Melanoma Research

Volumn 7, Issue 1, 1997, Pages 32-42

  Andalib, A R ^a   Lawry, J ^a   Ali, S A ^a   Murray, A K ^a   Sisley, K ^a   Silcocks, P ^a   Herlyn, M ^b   Rees, R C ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b WISTAR INSTITUTE   (United States)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

cytokine; ICAM 1; MHC class I and class II; NK LAK; primary and metastatic melanoma

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LUNG NEOPLASMS; LYMPHOCYTES; MELANOMA; MICE; MICE, SCID; TUMOR CELLS, CULTURED;

EID: 0031053247     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199702000-00006     Document Type: Article

References (51)

1. Clark W. Tumour progression and the nature of cancer. Br J Cancer 1991; 64: 631-644.
2. Menrad A, Herlyn M. Tumour progression, biology, and host response in melanoma, Curr Opin Oncol 1992; 4: 351-356.
3. Herlyn M. Molecular and Cellular Biology of Melanoma. Austin. TX: R.G. Landes, 1993; 21-43.
4. Herlyn M, Menrad A, Koprowski H. Structure, function, and clinical significance of human tumour antigens. J Natl Cancer Inst 1990; 82: 1883-1889.
5. Rak JW, Hegmann EJ, Lu C. Kerbel RS. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease-progression. J Cell Physiol 1994; 159: 245-255.
6. Lu C, Kerbel RS. Cytokines. growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr Opin Oncol 1994; 6: 212-220.
7. Makgoba MW, Sanders ME, Luce GEG, et al. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LEA-1-dependent adhesion in T-cell-mediated cytotoxicity. Eur J Immunol 1988; 18: 637-640.
8. Mortarini R, Belli F, Parmiani G, Anichini A. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumour-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. Int J Cancer 1990; 45: 334-341.
9. Storkus WJ, Dawson JR. Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. CRC Crit Rev Immunol 1991; 10: 393-416.
10. Pandolfi F, Trentin L, Boyle LA. et al. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumour-infiltrating lymphocytes. Cancer 1992; 69: 1165-1173.
11. Kageshita T, Wang Z, Calorini L, et al. Selective loss of human leucocyte class I allospecificties and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leucocyte antigens. Cancer Res 1993; 53: 3349-3354.
12. Moller P, Hammerling GJ. The role of surface HLA-A, B, C molecules in tumour immunity. Cancer Surv 1992; 13: 101-127.
13. Chikamatsu K, Eura M. Matsuoka H. et al. The role of major histocompatibility complex expression on head and neck cancer cells in the induction of autologous cytotoxic T lymphocytes Cancer Immunol Immunother 1994; 38: 358-364.
14. Cohen EP, Kim TS. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin Cancer Biol 1994; 5: 419-423.
15. Rothlein R, Czajkowski M, O'Neill MM, et al. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines: Regulation by pharmacologic agents and neutralizing antibodies. J Immunol 1988; 141: 1665-1669.
16. Kerbel RS. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol 1992; 141: 519-524.
17. Takahashi T, Ishikura, Iwai K, et al. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro. Cancer Immunol Immunother 1993; 36: 76-82.
18. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990; 9: 110-112.
19. Johnson JP, Lehmann JM, Stade BG, et al. Functional aspects of three molecules associated with metastatic development in human malignant melanoma. Invasion Metastasis 1989; 9: 338-350.
20. Natali P, Nicotra MR, Cavaliere R. et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990; 50: 1271-1278.
21. Huang YW, Richardson JA, Vitetta ES. Anti-CD54 (ICAM-1) has antitumour activity in SCID mice with human myeloma cells. Cancer Res 1995; 55: 610-616.
22. Miele ME, Bennett CF, Miller BE, et al. Enhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1. CD54) antisence oligonucleotides. Exp Cell Res 1994: 214: 231-241.
23. Yoneda K, Mori S, Takemura M, Noma A. Yamamoto A. Intercellular adhesion molecule-1 on cultured human melanoma cells: influence of cytokines. J Dermatol 1993; 20: 144-150.
24. Kirnbauer R, Charvat B, Schauer E, et al. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF beta and VB light. J Invest Dermatol 1992; 98: 320-326.
25. Kaufman DS, Schoon RA, Leibson PJ. MHC class 1 expression on tumour targets inhibits natural killer cell-mediated cytotoxicity without interfering with target recognition. J Immunol 1993; 150: 1429-1436.
26. Nouri AM, Hussain RF, Dos-Santos AV. Mansouri M, Oliver RT. Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing. Br J Cancer 1993; 67: 1223-1228.
27. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2 35-45.
28. Yanagihara K, Seyama T, Watanabe Y. Antitumour potential of interferon-gamma: retroviral expression of mouse interferon-gamma cDNA in two kinds of highly metastatic mouse tumour lines reduces their tumorigenicity. Nat Immun 1994; 13: 102-112.
29. Gattoni S, Calorini L, Simile MM, Ferrone S. Modulation by MHC class I antigens of the biology of melanoma cells. Melanoma Res 1993; 3: 285-289.
30. Anichini A, Mortarini R, Parmiani G. The role of cytokines in the modulation of cell surface antigens of human melanoma, Int J Biol Markers 1993; 8: 151-154.
31. Nouri AM. Hussain RF, Dos-Santos AV. et al. Induction of MHC antigens by tumour cell lines in response to interferons. Eur J Cancer 1992; 128: 1110-1115.
32. Stotter H, Wiebke EA, Tomita S, et al. Cytokines alter target cell susceptibility to lysis: II. Evaluation of tumour infiltrating lymphocytes. J Immunol 1989: 142: 1767-1773.
33. Weber JS, Jay G, Tanaka K, Rosenberg SA. Immunotherapy of a murine tumour with interleukin: 2. Increased sensitivity after MHC class I gene transfection. J Exp Med 1987; 166: 1716-1733.
34. Reiter Z. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity. CRC Crit Rev Immunol 1993; 13: 1-34.
35. Gronberg A, Ferm M, Tsai L, Kiessling R. Interferon is able to reduce tumour cell susceptibility to human leucocyte-activated killer (LAK) cells. Cell Immunol 1989; 118: 10-21.
36. Miyatake S, Kikuchi H, Oda Y, et al. Decreased susceptibility of lined human gliosarcoma cells to lymphokine-activated killer cell cytolysis by gamma-interferon treatment. Cancer Res 1990; 50: 596-600.
37. Bacon C, Lawry J, Rees RC. TNFα protects SW742 human colon carcinoma cells against non-MHC-restricted cytolysis. Immunol Lett 1993; 38: 215-222.
38. Yanase M, Tsukamoto T, Kumamoto Y, et al. Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment. Cancer Immunol Immunother 1994; 39: 22-26.
39. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-494.
40. Van Duinen SG, Ruiter DJ, Broecker EA, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma, Cancer Res 1990; 48: 1019-1025.
41. Litwin V, Gumperz J, Parham P, et al. Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles. and influence of the target cell type, J Exp Med 1993; 178: 1321-1336.
42. Concha A, Esteban F, Cabrera T, et al. Tumour aggres siveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991; 2: 47-54.
43. Garrido F, Ruiz-Cabello F. MHC expression on human tumours - its relevance for local tumour growth and metastasis. Semin Cancer Biol 1991; 2: 3-10.
44. Worm M. Schadendorf D, Czarnetzki BM. Responsiveness to interferon treatment of human melanoma cells correlates to immunophenotype. Melanoma Res 1993; 3: 29-33.
45. Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U. Growth-regulatory factors for normal, premalignant. and malignant human cells in vitro. Adv Cancer Res 1990; 54: 213-234.
46. Cornil I. Theodorescu D. Man S. et al. Fibroblast cell interactions with human melanoma cells attect tumour cell growth as a function of tumour progression. Proc Natl Acad Sci USA 1991: 88: 6028-6032.
47. Lu C, Rak JW, Kobayashi H, et al. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. Cancer Res 1993; 53: 2708-2711.
48. Lu C. Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumour progression. Proc Natl Acad Sci USA 1992; 89: 9215-9219.
49. Schwarz LC. Gingras MC. Goldberg G, et al. Loss to growth factor dependence and conversion of transforming growth factor-beta-1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res 1988: 48: 6999-7003.
50. Grabe C, Krasagakis K. Effects of interferons and Cytokines on melanoma cells. J Invest Dermatol 1993; 100: 239S-244S.
51. Nagelkerke NJD. A note on a general definition of the coefficient of determinations. Biometrika 1991; 78: 691-692.